- Home
- Automated
- NDF A-Z listing
- Ustekinumab [Stelara]
U
Ustekinumab [Stelara]
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Ustekinumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
01/07/2022 Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
The Ministry of Health’s Drug Advisory Committee has recommended:
Tofacitinib 5 mg tablet for treating adults with moderately to severely active ulcerative colitis (UC) who have failed conventional therapy and/or anti-TNFα biologics; and
Vedolizumab 300 mg/vial powder for concentrate for solution for infusion for treating adults with moderately to severely active Crohn’s disease (CD) who have failed both conventional therapy and anti-TNFα biologics.
Subsidy status
[R] Tofacitinib 5 mg tablets and vedolizumab 300 mg/vial powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
[R] Tofacitinib and vedolizumab should be used in line with the clinical criteria for initial and continuing prescriptions for patients with UC and CD in the respective MAF checklists.
[R] Listing on MAF will be implemented on 1 July 2022.
[NR] MAF assistance does not apply to any formulations or strengths of ustekinumab for treating CD and UC.
03/05/2017 Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended ustekinumab to be listed on the Medication Assistance Fund (MAF) for the treatment of chronic plaque psoriasis and psoriatic arthritis.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Stelara Injection, Solution 45 mg/0.5 mL |
|
Stelara Injection, Solution 90 mg/1 mL |
|
Stelara Infusion, Solution Concentrate 130 mg/vial |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |